Welcome to our dedicated page for Inspiremd news (Ticker: NSPR), a resource for investors and traders seeking the latest updates and insights on Inspiremd stock.
Overview of InspireMD Inc.
InspireMD Inc. is a United States based medical device company that specializes in the development and commercialization of advanced stent platforms for the treatment of complex vascular and coronary diseases. With its innovative MicroNet stent technology integrated into its devices, InspireMD addresses the challenges of carotid artery stenosis and stroke prevention, providing acute and durable, stroke-free outcomes. The company's operations are underpinned by rigorous clinical evaluation, robust research methodologies, and participation in influential interventional conferences that underscore its commitment to clinical excellence and data-driven practice.
Core Business and Technology
At its core, InspireMD leverages a proprietary design that combines a self-expandable nitinol stent with a MicroNet mesh to offer comprehensive embolic protection during carotid interventions. This dual-component system is engineered to optimize acute performance while also ensuring sustained long-term efficacy in stroke prevention. The integration of advanced biomaterials with innovative stenting methods positions InspireMD as a noteworthy player in the realm of vascular interventional devices.
Clinical Evidence and Global Reach
InspireMD has built its reputation on a foundation of strong clinical evidence, with multiple clinical trials across the United States and Europe validating the safety and efficacy of its devices. The products have been evaluated in pivotal studies, where key endpoints such as the reduction of major adverse events have been meticulously documented. The company's involvement in international clinical trials and its presence at globally recognized congresses highlight its commitment to establishing credibility and continuous improvement in medical practice.
Market Position and Competitive Landscape
Within the competitive landscape of medical devices, InspireMD distinguishes itself through its specialized focus on carotid stenting systems. The company has cultivated a niche by addressing unmet needs in the management of carotid artery disease through the integration of state-of-the-art technology with clinical validation. Its expansive network, spanning markets in Europe, the United States, and other key regions, further reinforces its status as a globally aware and clinically driven entity.
Operational Model and Regulatory Focus
The business model of InspireMD revolves around direct sales of its innovative stent systems to healthcare providers, bolstered by ongoing clinical trials that support regulatory compliance and product improvement. By streamlining manufacturing and enhancing operational capabilities in strategic regions, such as its new headquarters in the U.S., the company strengthens its commercial infrastructure in anticipation of broad-based market adoption. Regulatory milestones, including Pre-Market Approval (PMA) submissions and inclusion in major clinical trials, underscore the adept handling of compliance and product safety standards.
Commitment to Clinical Excellence and Innovation
InspireMD remains committed to advancing the field of carotid interventions by continuously refining its technology based on rigorous clinical study outcomes. The company leverages its proprietary technology to offer sustainable solutions for stroke prevention, ensuring that both the short-term procedural success and long-term patient outcomes are optimized for safety and efficacy. This constant drive for innovation not only enhances patient care but also builds long-term trust with healthcare providers and regulators.
Summary
- Innovative Technology: Utilizes proprietary MicroNet stent technology for enhanced embolic protection.
- Rigorous Clinical Validation: Backed by multiple clinical trials across key international markets.
- Global Reach: Maintains a presence in major markets with a focus on regulatory excellence and clinical performance.
- Focused Operations: Streamlines its business model around direct sales and a robust global operational framework.
This detailed exploration of InspireMD Inc. provides an informative and comprehensive view of its strategic positioning in the medical device industry, delivering clear insights for investors and industry stakeholders.
InspireMD (Nasdaq: NSPR), the developer of CGuard™ Prime carotid stent system for carotid artery disease treatment and stroke prevention, has announced its participation in the upcoming 24th Annual Needham Virtual Healthcare Conference.
The presentation is scheduled for Wednesday, April 9, 2025, at 8:00AM Eastern Time / 5:00AM Pacific Time. Investors and interested parties can access a live audio webcast of the presentation, with a replay available for 90 days through the company's website at inspiremd.com in the News & Events section.
InspireMD (NSPR) reported its Q4 and full-year 2024 financial results, highlighting record quarterly revenue of $1.95M and 3.5K units in served markets. The company achieved a 10.7% revenue increase in Q4 2024 compared to Q4 2023.
Key developments include the FDA engagement for CGuard Prime carotid stent system's PMA application, with anticipated approval in H1 2025. The company established its headquarters in Miami and initiated the CGUARDIANS II pivotal study for TCAR procedures.
Financial highlights: Full-year 2024 revenue increased 13% to $7.01M, though gross margin decreased to 21.5% from 29.1%. Q4 operating expenses rose 55.8% to $9.84M, primarily due to US personnel expansion and commercial preparation costs. The company ended 2024 with $34.64M in cash and marketable securities.
InspireMD (NSPR), developer of the CGuard™ Prime carotid stent system for treating carotid artery disease and stroke prevention, has scheduled its fourth quarter and full year 2024 financial results announcement for March 12, 2025.
The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss financial results and recent highlights. Investors can join via phone (domestic: 1-800-579-2543, international: 1-785-424-1789) or through the company's investor relations website.
InspireMD (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for stroke prevention, announced that its Compensation Committee has approved inducement grants to six new non-executive employees totaling 138,442 shares of restricted stock.
These grants were made outside of InspireMD's 2021 Equity Compensation Plan with a grant date of February 5, 2025. The inducement plan is exclusively used for equity awards to individuals who were not previously employees of InspireMD, or following a bona fide period of non-employment, as an inducement for joining the company.
The restricted stock follows a three-year vesting schedule, with one-third vesting on the first anniversary and the remainder vesting in two equal installments on the second and third anniversaries, contingent upon continued employment with InspireMD as of these vesting dates.
InspireMD (NSPR) and NAMSA announced their partnership for the CGUARDIANS II pivotal study of the CGuard Prime™ 80 cm carotid stent system for Transcarotid Artery Revascularization (TCAR) procedures. The study, which enrolled its first patient in December 2024, aims to evaluate the safety and effectiveness of the TCAR procedure using CGuard Prime with an FDA-authorized embolic protection device.
The prospective, multi-center, single-arm pivotal study targets a minimum enrollment of 50 evaluable patients at high risk for adverse events from carotid endarterectomy. With over 30,000 TCAR procedures performed annually in the U.S., this represents a significant market expansion opportunity for InspireMD's carotid stenting solutions.
InspireMD (NSPR), developer of the CGuard™ Prime carotid stent system, announced that its Compensation Committee has approved inducement grants for a new non-executive employee. The grant consists of 18,000 shares of restricted stock, issued outside the company's 2021 Equity Compensation Plan, with a grant date of January 7, 2025.
The restricted stock will vest over three years, with one-third vesting on the first anniversary and the remaining portions vesting equally on the second and third anniversaries, contingent upon continued employment. This grant complies with Nasdaq Listing Rule 5635(c)(4) and is specifically designed for new employees or those returning after a bona fide period of non-employment.
InspireMD (NSPR), developer of the CGuard™ Prime carotid stent system, has announced inducement grants for nine new non-executive employees. The Compensation Committee approved a total of 372,135 shares of restricted stock outside the company's 2021 Equity Compensation Plan, with a grant date of January 7, 2025.
The restricted stock grants are structured with a three-year vesting period: one-third vests after the first year, with the remaining shares vesting equally on the second and third anniversaries of the grant date. These grants, made under Nasdaq Listing Rule 5635(c)(4), are specifically designed as employment inducements for new hires who were not previously InspireMD employees.
InspireMD (NSPR) announced that Chief Financial Officer Craig Shore will retire after 15 years with the company. Shore will remain in his position until a successor is appointed and will assist in the transition. The announcement comes as the company anticipates potential FDA approval in the first half of 2025 for its CGuard™ Embolic Prevention Stent System.
CEO Marvin Slosman praised Shore's commitment to building the company's position as a global leader in carotid interventions. Shore expressed confidence in the company's future growth trajectory and its leadership in carotid intervention and stroke prevention. The company has initiated a search for a new CFO.
InspireMD (NSPR) has announced the enrollment of its first patient in the CGUARDIANS II clinical trial, evaluating the CGuard Prime Carotid Stent System in TCAR procedures. The study, conducted at Good Samaritan Hospital in Cincinnati, enrolled its first patient under Dr. Patrick Muck, who serves as both site principal investigator and co-lead investigator.
The CGUARDIANS II is a prospective, multi-center, single-arm pivotal study aiming to enroll a minimum of 50 evaluable patients. The trial will evaluate acute device success and technical success of CGuard Prime when used with FDA-cleared TCAR neuro-protection systems. The company is approaching potential FDA approval for CGuard Prime with a CAS indication in first half of next year, targeting a TCAR market of approximately 30,000 U.S. procedures annually.
InspireMD (NSPR) has appointed Scott R. Ward to its Board of Directors. Ward, who most recently served as CEO and President of Cardiovascular Systems until its acquisition by Abbott in April 2023, brings over 40 years of healthcare industry experience, including 30 years at Medtronic in senior leadership roles. The appointment comes as InspireMD approaches potential U.S. approval of its CGuard Prime carotid stent system. Ward's extensive operational experience in the cardiovascular space is expected to contribute to the company's strategy in advancing its carotid platform and pipeline innovations, including CAS, TCAR, and Neuro focus.
FAQ
What is the current stock price of Inspiremd (NSPR)?
What is the market cap of Inspiremd (NSPR)?
What is the core focus of InspireMD Inc.?
How does the MicroNet stent technology work?
In which markets does InspireMD operate?
What clinical evidence supports InspireMD's products?
How does InspireMD differentiate itself from its competitors?
What steps has InspireMD taken towards regulatory approval?
How does InspireMD generate revenue?
What advantages does InspireMD’s technology offer in stroke prevention?
